Get the Stockscreener App
44.74
9.02%
3.70
After Hours:
44.54
-0.20
-0.45%
Avidity Biosciences Inc stock is traded at $44.74, with a volume of 12.96M.
It is up +9.02% in the last 24 hours and down -3.22% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$41.04
Open:
$43.06
24h Volume:
12.96M
Relative Volume:
4.59
Market Cap:
$5.76B
Revenue:
$10.12M
Net Income/Loss:
$-280.49M
P/E Ratio:
-15.48
EPS:
-2.89
Net Cash Flow:
$-188.51M
1W Performance:
-11.16%
1M Performance:
-3.22%
6M Performance:
+37.20%
1Y Performance:
+8.30%
1-Day Range:
$42.97
$46.23
1-Week Range:
$35.70
$50.05
52-Week Range:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
44.74 | 5.97B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Wilson Sonsini Advises Avidity Biosciences on Patent Matters Related to $600 Million Upsized Public Offering - Wilson Sonsini
Avidity Biosciences Announces Major Stock Offering - TipRanks
Avidity Biosciences files for offering of 15 million shares of common stockSEC filing - MarketScreener
Avidity Biosciences (NASDAQ:RNA) Given New $65.00 Price Target at Needham & Company LLC - MarketBeat
Avidity Biosciences stock price target raised to $65 at BofA Securities - Investing.com Canada
Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
A new biotech fund in the Middle East; Xspray preps for FDA decision on Dasynoc - Endpoints News
HC Wainwright Adjusts Avidity Biosciences Price Target to $87 From $68, Maintains Buy Rating - MarketScreener
Avidity Biosciences reports data from DMD treatment trials - MSN
Avidity Biosciences price target raised to $87 from $68 at H.C. Wainwright - TipRanks
Avidity Biosciences prices $600M stock offering - MSN
Avidity Biosciences Prices $600 Million Equity Offering - MarketScreener
Avidity Biosciences prices upsized public offering at $600 million By Investing.com - Investing.com Australia
Avidity Biosciences prices upsized public offering at $600 million - Investing.com
Avidity Biosciences (NASDAQ:RNA) Director Troy Edward Wilson Sells 29,500 Shares - MarketBeat
Avidity Biosciences prices upsized public offering at $40 per share - MarketScreener
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - PR Newswire
Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota - Seeking Alpha
Top Midday Decliners - MarketScreener
Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion - TipRanks
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA - BioSpace
Why Is Avidity Biosciences Stock Down 20% Pre-market Today? - MSN
Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
S&P 500 Futures Climb in Premarket Trading; Avidity Biosciences, Installed Bldg Products Lag - Barron's
Avidity Biosciences, Inc. $RNA Shares Bought by Alyeska Investment Group L.P. - MarketBeat
Avidity Biosciences Amends Share Plan Amid Trial Success - MSN
Brokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) PT at $67.00 - MarketBeat
Avidity Biosciences - TipRanks
Avidity Biosciences’ Del-Zota Shows Promising Data in DMD, Justifying Buy Rating and $56 Price Target - TipRanks
Avidity Biosciences announces $500 million public stock offering - Investing.com
Avidity claims 'unprecedented' functional benefits with oligo DMD treatment - FirstWord Pharma
Avidity Biosciences Plans $500 Million Public Offering of Shares - MarketScreener
Transcript : Avidity Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Avidity Biosciences Stock Surges on Promising Trial Results - TipRanks
Raymond James Financial Inc. Decreases Position in Avidity Biosciences, Inc. $RNA - MarketBeat
$500 Million Stock Offering: Avidity Biosciences Aims to Advance Three Late-Stage RNA Therapeutics Programs - Stock Titan
Avidity Drug Shows Yearlong Gains In Duchenne Muscular Dystrophy TrialAvidity Biosciences (NASDAQ:RNA) - Benzinga
Patients With DMD Treated With Avidity Biosciences’ Antibody Oligonucleotide Conjugate Del-Zota Show Functional Improvements - CGTLive®
Avidity Biosciences: Promising Phase 1/2 Trial Results and FDA Agreement Boost Buy Rating - TipRanks
Avidity touts disease reversal potential of DMD therapy - Yahoo Finance
Raymond James reiterates Strong Buy on Avidity Biosciences stock By Investing.com - Investing.com Canada
Avidity Biosciences stock maintains Buy rating at TD Cowen on DMD drug data - Investing.com
Avidity’s DMD therapy shows functional improvements after one year By Investing.com - Investing.com Nigeria
Avidity shares functional data ahead of plans to submit Duchenne exon skipping drug by year's end - Endpoints News
Raymond James reiterates Strong Buy on Avidity Biosciences stock - Investing.com
Avidity Says Potential Duchenne Muscular Dystrophy Treatment Shows Disease Reversal in Phase 1/2 Trial - MarketScreener
Avidity Biosciences' del-zota shows disease reversal in key endpoints - MarketScreener
Avidity stock rises after del-zota shows disease reversal in DMD44 trial - Investing.com Canada
Avidity’s DMD therapy shows functional improvements after one year - Investing.com
25% Dystrophin Increase & 80% CK Reduction: Avidity's Del-zota Achieves Breakthrough in DMD44 Treatment - Stock Titan
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44 - The Malaysian Reserve
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):